T. Rowe Price Associates
VYGR icon

T. Rowe Price Associates’s Voyager Therapeutics VYGR Stock Holding History

T. Rowe Price Associates’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545K Buy
155,526
+38,448
+33% +$146K ﹤0.01% 2591
2026
Q1 		$452K Sell
117,078
-404,573
-78% -$1.59M ﹤0.01% 2509
2025
Q4 		$2.05M Sell
521,651
-60,048
-10% -$266K ﹤0.01% 1741
2025
Q3 		$2.72M Sell
581,699
-29,172
-5% -$106K ﹤0.01% 1610
2025
Q2 		$1.9M Sell
610,871
-11,651
-2% -$37.6K ﹤0.01% 1659
2025
Q1 		$2.1M Sell
622,522
-239,910
-28% -$1.12M ﹤0.01% 1592
2024
Q4 		$4.89M Sell
862,432
-43,388
-5% -$280K ﹤0.01% 1292
2024
Q3 		$5.3M Sell
905,820
-83,729
-8% -$609K ﹤0.01% 1279
2024
Q2 		$7.83M Sell
989,549
-52,381
-5% -$439K ﹤0.01% 1146
2024
Q1 		$9.7M Buy
1,041,930
+37,144
+4% +$314K ﹤0.01% 1117
2023
Q4 		$8.48M Sell
1,004,786
-169,301
-14% -$1.23M ﹤0.01% 1128
2023
Q3 		$9.1M Sell
1,174,087
-55,894
-5% -$510K ﹤0.01% 1086
2023
Q2 		$14.1M Buy
1,229,981
+328,516
+36% +$3.4M ﹤0.01% 1018
2023
Q1 		$6.95M Buy
901,465
+104,144
+13% +$828K ﹤0.01% 1114
2022
Q4 		$4.86M Sell
797,321
-46,390
-5% -$264K ﹤0.01% 1199
2022
Q3 		$5M Buy
843,711
+15,761
+2% +$101K ﹤0.01% 1202
2022
Q2 		$4.89M Buy
827,950
+782,850
+1,736% +$5.29M ﹤0.01% 1426
2022
Q1 		$344K Sell
45,100
-45,800
-50% -$204K ﹤0.01% 2495
2021
Q4 		$246K Buy
90,900
+1,500
+2% +$5.12K ﹤0.01% 2687
2021
Q3 		$235K Buy
89,400
+25,900
+41% +$84.1K ﹤0.01% 2663
2021
Q2 		$262K Sell
63,500
-1,878
-3% -$8.51K ﹤0.01% 2631
2021
Q1 		$308K Buy
+65,378
New +$446K ﹤0.01% 2558
2019
Q1 		– Sell
-131,202
Closed -$1.23M – 2565
2018
Q4 		$1.23M Sell
131,202
-111,232
-46% -$1.43M ﹤0.01% 1717
2018
Q3 		$4.59M Buy
242,434
+209,580
+638% +$4.02M ﹤0.01% 1465
2018
Q2 		$642K Buy
+32,854
New +$649K ﹤0.01% 2036
2017
Q3 		– Sell
-150,384
Closed -$1.35M – 2591
2017
Q2 		$1.35M Buy
150,384
+91,093
+154% +$917K ﹤0.01% 1672
2017
Q1 		$785K Sell
59,291
-43,764
-42% -$531K ﹤0.01% 1883
2016
Q4 		$1.31M Buy
+103,055
New +$1.32M ﹤0.01% 1685

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

T. Rowe Price Associates's VYGR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Voyager Therapeutics (VYGR) stake by 33% in Q2 2026, buying an estimated $146K and bringing the position to 155,526 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

T. Rowe Price Associates first reported a position in VYGR in Q4 2016 and has held it in 28 quarters since. The position peaked at $14.1M in Q2 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • T. Rowe Price Associates held 155,526 shares of Voyager Therapeutics worth $545K as of Q2 2026.
  • T. Rowe Price Associates bought 38,448 Voyager Therapeutics shares in Q2 2026, an estimated $146K.
  • Voyager Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2591 holding.
  • T. Rowe Price Associates first reported a position in Voyager Therapeutics in Q4 2016 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Voyager Therapeutics position peaked at $14.1M in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.